You are here: Industry Insights > Jardiance

News List

FDA Approves Treatment for Wider Range of Patients with Heart Failure FDA
February 25, 2022
The U.S. Food and Drug Administration approved Jardiance (empagliflozin) to reduce the risk of cardiovascular death and hospitalization for heart failure in adults.
FDA grants priority review to Boehringer-Lilly’s Jardiance for heart failure Pharmaceutical-Technology
November 15, 2021
Boehringer Ingelheim Pharmaceuticals and Eli Lilly have obtained the US Food and Drug Administration (FDA) priority review for Jardiance (empagliflozin) to potentially treat heart failure...
Jardiance becomes first SGLT2 inhibitor to show benefit in HFpEF pharmatimes
July 07, 2021
Eli Lilly and Boehringer Ingelheim have revealed positive results from a Phase III study of its SGLT2 inhibitor Jardiance in patients with heart failure with preserved ejection fraction (HFpEF).
European Commission approves Jardiance to treat heart failure expresspharma
June 22, 2021
The European Commission has granted marketing authorization for Jardiance (empagliflozin) as a treatment for adults with symptomatic chronic heart failure with reduced ejection fraction (systolic heart failure), Boehringer Ingelheim and Eli Lilly and ...
FDA dismisses Jardiance for type I diabetes pharmatimes
March 24, 2020
Eli Lilly and Boehringer Ingelheim have received a complete response letter from the US Food and Drug Administration (FDA) regarding the filing of Jardiance (empagliflozin) ...
Jardiance bags FDA Fast Track designation pharmatimes
March 19, 2020
The US Food and Drug Administration (FDA) has granted Boehringer Ingelheim Fast Track designation for the investigation of Jardiance (empagliflozin).
Fast Track designation granted to chronic kidney disease treatment europeanpharmaceuticalreview
March 17, 2020
The US FDA has granted Fast Track designation to Jardiance® for the treatment of chronic kidney disease.
FDA Grants Fast Track Designation to Jardiance for Chronic Kidney Disease americanpharmaceuticalreview
March 16, 2020
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of Jardiance® (empagliflozin) to reduce the risk of kidney disease progression ...
Jardiance phase 3 exercise ability studies in chronic heart failure fail to meet primary endpoint pharmaceutical-business-review
December 20, 2019
Jardiance, a type 2 diabetes drug developed by Boehringer Ingelheim and Eli Lilly and Company (Lilly), failed to meet the primary endpoint of two late-stage exercise ability trials in chronic heart failure.
Boehringer Ingelheim, Lilly Provides Update on Jardiance Study americanpharmaceuticalreview
December 18, 2019
Boehringer Ingelheim and Eli Lilly and Company announced results from the EMPERIAL-Reduced and EMPERIAL-Preserved trials related to functional endpoints with Jardiance® (empagliflozin) ...

Previous page 1 2 Next page